The ICN2 Nanobiosensors and Bioanalytical Applications (NanoB2A) has joined forces with Vall d'Hebron University Hospital and the Vall d'Hebron Research Institute (VHIR) to launch #SexyCheck, a campaign designed to raise awareness among young people about the prevention of sexually transmitted infections (STIs). The campaign is part of the DIGITS project, funded by Barcelona City Council and the "la Caixa" Foundation, which is focused on developing new solutions for the diagnosis of these infections.

The number of cases of STIs, such as chlamydia and gonorrhoea, has increased significantly over the past decade, particularly among young people. Now, more than 60% of new diagnoses are made in people under the age of 30. Often, these infections cause no symptoms, which can delay diagnosis and treatment, increasing the risk of more serious health complications.

With the slogan "getting a check is the sexiest thing you can do", the campaign aims to challenge the stigma surrounding STI testing and promote a culture of self-care based on clear, accessible, objective information. Over the coming weeks, the campaign will be launched through digital communication materials, as well as posters and leaflets to be distributed in healthcare and educational institutions.

Nanotechnology: improving STI diagnosis

The DIGITS project focuses on developing new tools to improve the diagnosis of STIs. As part of this effort, the collaboration between the different research teams has led to the development of a nanotechnology-based biosensor capable of detecting chlamydia and gonorrhoea within minutes from a urine sample.

This technology provides a quicker, more affordable and more accessible alternative to traditional diagnostic methods, which require specialised laboratory facilities. Implementing this technology could help bring early STI diagnosis closer to primary care and other community healthcare settings. The biosensor was developed by the Nanobiosensors and Bioanalytical Applications Group, in collaboration with researchers from the Vall d'Hebron Research Institute (VHIR) and Vall d'Hebron University Hospital.

Photo credits: Vall d'Hebron University Hospital.